Source: Chaozhou Daily
Facing the epidemic of the novel coronavirus, Guangdong Hybribio Biotech Co., Ltd. (hereinafter referred to “Hybribio”) has urgently set up a research team to invest in the development of test kits. Through the strict control of quality and production process, Hybribio completed the development of two COVID-19 diagnostic kits on January 29, with the confirmation of stability, reliability, and accuracy. The journalist was informed that the two kits can be used to quickly recognize and identify suspected patients, and a test report can be issued in about 2 hours. After the diagnostic reagents have passed the emergency approval, Hybribio will donate 20,000 diagnostic reagents to Hubei Province and Chaozhou City to support the local work for health and epidemic prevention.

Liejun Li, senior director of R&D department of Hybribio, told the journalist that the two kits successfully developed are the COVID-19 Real-Time PCR Kit (RT-PCR method) and the COVID-19 Sequencing kit (Sanger Sequencing method). The two products can be used to quickly recognize and identify suspected patients during incubation period, and assist medical institutions and disease control departments to take timely and effective prevention and control arrangements. However, the above two kits are only used for the detection of novel coronaviruses and not for treatment.

“Due to the tight schedule, the above products are currently only for scientific research and have not yet obtained a product registration certificate. However, Hybribio has already submitted an emergency approval application for medical devices to the drug regulatory authority and provided the assay kit to disease control departments and medical institutions for detection. It also helped the government and health departments of prevention and control to screening of infected patients during incubation period. ” Li Liejun said.
“After the testing reagents have passed the emergency approval, Hybribio will donate 20,000 diagnostic reagents to Hubei Province and Chaozhou City to support the local health and epidemic prevention work.” Said by Chen Yi, who is the general manager of Hybribio. He further told the journalist that, as a leader and national enterprise in the field of nucleic acid testing and independent clinical laboratories, Hybribio will strictly follow the guidelines issued by the National Health Commission to implement various safety measures and fully cooperate with the country on defense of novel coronavirus as well as providing powerfully support for the lives and health of people.
According to the Notice on Further Strengthening the Detection of Novel Coronavirus Nucleic Acids in the Province issued by the Headquarter of Novel Coronavirus Infection Pneumonia Epidemic Prevention and Control of Hubei Province on January 27, 2020, Wuhan Hybribio Medical Laboratory Co., Ltd., subsidiary of Hybribio, has been included in the list of third-party institutions that can carry out the detection of novel coronavirus nucleic acid (the 1st batch). In addition, Hybribio has selected some professionals of medical testing as part of medical team of Chaozhou to support the laboratory medicine of COVID-19 in the epidemic area. The list has been submitted to the government departments in Chaozhou.